Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728)
- PMID: 187332
Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728)
Abstract
The synthesis and isolation of two derivatives of 2-amino-1,3,4-thialdiazole(aminothiadiazole) are described. The derivatives are a nicotinamide adenine dinucleotide (NAD) analog prepared by an exchange reaction with NAD in the presence of nicotineamide adenine dinucleotide glycohydrolase and a presumed aminothiadiazole mononucleotide prepared by treatment of the NAD analog with nucleotide pyrophosphatase. Both derivatives are potent inhibitors of inosine 5'-phosphate (IMP) dehydrogenase obtained from leukemia L1210 cells. The NAD analog is a pseudoir-reversible inhibitor of the enzyme, noncompetitive with either IMP or NAD. The aminothiadiazole mononucleotide has a K1 of about 0.1 muM, is competitive with IMP, and is uncompetitive with NAD: the inhibition appears to be reversible by Ackermann-Potter analysis. A metabolite of [5-14C]aminothiadiazole is formed in L1210 cells in vivo to a level of 0.3 nmole/10(9) cells. Retention volume of the metabolite on a high-pressure liquid chromatography system is the same as that of the aminothiadiazole mononucleotide prepared as described above. These results suggest that IMP dehydrogenase is the site of action for aminothiadiazole metabolites as was indicated by earlier observations. There is no evidence that the NAD analog is formed in vivo. Nicotinamide prevented formation of the mononucleotide in vivo. Therefore, since formation and cleavage of the NAD analog apparently are not the route to the thiadiazole nucleotide, some other pathway for the metabolism of nicotinamide may be involved such as the action of a phosphoribosyltransferase or the sequential action of a nucleoside phosphorylase and a nucleoside kinase.
Similar articles
-
Effects of 2-amino-1,3,4-thiadiazole on ribonucleotide pools of leukemia L1210 cells.Cancer Res. 1976 Apr;36(4):1375-8. Cancer Res. 1976. PMID: 130972
-
Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.Adv Enzyme Regul. 1983;21:271-303. doi: 10.1016/0065-2571(83)90019-5. Adv Enzyme Regul. 1983. PMID: 6152729
-
Inhibitors of inosinate dehydrogenase.Biochem Int. 1987 Feb;14(2):211-8. Biochem Int. 1987. PMID: 2883976
-
NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity.Acta Biochim Pol. 1996;43(1):183-93. Acta Biochim Pol. 1996. PMID: 8790723 Review.
-
Aminothiadiazoles.Cancer Chemother Pharmacol. 1980;4(4):215-20. doi: 10.1007/BF00255264. Cancer Chemother Pharmacol. 1980. PMID: 7002341 Review.
Cited by
-
Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.Antimicrob Agents Chemother. 1990 Nov;34(11):2156-63. doi: 10.1128/AAC.34.11.2156. Antimicrob Agents Chemother. 1990. PMID: 2073106 Free PMC article.
-
Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line.Proc Natl Acad Sci U S A. 1978 Jul;75(7):3042-4. doi: 10.1073/pnas.75.7.3042. Proc Natl Acad Sci U S A. 1978. PMID: 210448 Free PMC article.
-
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.Invest New Drugs. 1988 Jun;6(2):97-103. doi: 10.1007/BF00195367. Invest New Drugs. 1988. PMID: 3170135
-
Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA:NSC 4728).Cancer Chemother Pharmacol. 1986;16(3):287-91. doi: 10.1007/BF00293994. Cancer Chemother Pharmacol. 1986. PMID: 2938841
-
Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism.J Inherit Metab Dis. 1989;12(2):184-96. doi: 10.1007/BF01800725. J Inherit Metab Dis. 1989. PMID: 2502677 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources